Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASE SBS 5
2024-512486-14-00Phase 3Authorised
- Sponsor
- Zealand Pharma
- Start
- Jan 2026
- Modality
- Peptides
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in short bowel syndrome (SBS) and intestinal failure (IF) comparing Glepaglutide with Placebo (2 arms). Primary endpoint: Change in weekly parenteral support volume from baseline to Week 24. Planned start Jan 2026; status: authorised.
02
Drugs
glepaglutide
03
Conditions
short bowel syndrome (SBS)intestinal failure (IF)
Beyond the preview
Go deeper on 2024-512486-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512486-14-00.